

Pediatric Drug Delivery

Evolving Dosage Forms, Emerging Opportunities



Pediatric Drug Delivery: Evolving Dosage Forms, Emerging Opportunities

Greystone Associates is pleased to announce the publication of a new market study. **Pediatric Drug Delivery: Evolving Dosage Forms, Emerging Opportunities** is a comprehensive evaluation and analysis of the technology, products and participants providing the driving force behind this evolving segment of the drug delivery sector.

The study is designed to provide drug company decision makers, drug delivery developers, device designers, healthcare marketers, and supply chain participants with a detailed understanding of the economics, technologies, formulation factors, and commercial opportunities for drugs developed to meet the therapeutic needs and physiological limitations of pediatric patients. Provider organization business managers, healthcare administrators and investors will also benefit from this study.

Targeted Approaches for a Commercially Important Market Segment

Recent recognition and industry acceptance of the unique therapeutic needs of pediatric patients has led to regulatory activity and development programs that are re-defining this market segment. To encourage drug developers to perform clinical testing in pediatric age groups for drugs anticipated to be used for children, the FDA and the European Commission have adopted special rules and guidance. The result has been a push by developers and formulators emphasizing the creation of formulations engineered and packaged specifically for children to meet the needs of pediatric patient populations. Several factors are driving the growth of the pediatric drug sector. The pediatric sector is forecast to be one of the fastest growing drug markets over the next ten years. By circumventing the normal clinical trial and regulatory approval process, off-label prescribing and extemporaneous formulations add risk to pediatric prescribing. The growing availability of drugs targeted for childhood illnesses is focusing efforts on child-friendly delivery methods.




Table of Contents

Executive Summary

Pediatric Drug Market Dynamics

Factors Driving the Pediatric Market
Prevalence of Solid Oral Dosage Form (SODF)
Alternatives to SODF
Competitive Landscape

The Pediatric Market

Market Segments
 Infant
 Children/Pre-Adolescent
 Adolescent
Demographic Factors
Age-related Disease Factors

Pediatric Drug Design Factors

Age-Appropriate Formulations
Ease of Administration
Release Rate/Kinetics
Safety
Cost

Pediatric Formulation Technologies

Buccal & Transmucosal Films
Chewable Tablets
 Product Strategies
 Products and Pipeline Prospects
Fast-Dissolve Formulations
 Proprietary Technologies
 Commercial Products
Syrups & Liquids
Oral Sprays
Sublingual Formulations

Pediatric Formulation Factors

Dosing/Controlled Release
Matrix Technologies

Particle Engineering
Tablet/Capsule Technology
Taste Masking
Emerging Technologies

Analysis of Important Pediatric Therapeutic Segments

ADHD
Allergies
Analgesics
Antibiotics
Antivirals
Asthma
Childhood Cancers
Cough/Cold Medications
Dermatology
Growth Deficiencies
Neurology
Vaccines

Market Factors

Extemporaneous Formulations
Regulations
 Best Pharmaceuticals for Children Act
 Pediatric Exclusivity
 Pediatric Priority List
 Pediatric Research Equity Act
European Regulation on Medicines for Children
Pediatric Drug Studies
Pediatric Re-labeling
Drug Patent Life and IP Factors

Business Risk and Opportunity Factors

Technology Differentiation
Pediatric Labeling
Product Branding
Formulation Approaches
Technology/Pharma Company Alliances

Pediatric Drugs - Sector Company Profiles

Feature Summary

- Analyzes and evaluates pediatric formulation and drug delivery activity and assesses the market potential of existing and probable future pediatric products
- Assesses key pediatric drug therapy segments
- Provides detailed evaluations of pediatric drug formulation and delivery technology market factors and evolving business opportunities
- Charts market segment data and forecasts technology market share to 2012
- Profiles pediatric drug formulation participants, their technology development activities, business strategies, and corporate alliances and affiliations
- Assesses the importance of pharmaceutical partnerships and design collaborations on pediatric drug market developments
- Evaluates the impact of economic, technology, and regulatory factors on pediatric drug markets

Report Format and Availability

This report is available electronic format. A site license for a single physical location and an Enterprise license are also available.

Methodology

Research methodology is based on primary research in the form of in-depth interviews with key market participants, technology developers, distributors, industry experts, and market influencers, a list that includes regulatory officials, industry trade groups, and materials standards organizations.

Primary data is evaluated and normalized against secondary sources including trade journal articles, technical literature, industry publications, company data sheets and published information, and statistical data from government agencies and trade associations.

Forecasts and projections of market demand and future market activity are derived using standard modeling and statistical techniques.

About Greystone Associates

Greystone Associates is a medical technology consulting firm focused on the areas of medical market strategy, product commercialization, venture development, and market research. We assist medical and healthcare market participants in achieving their business objectives through the creation of detailed development strategies, product commercialization programs, and comprehensive market and technology research and analysis.

Our market research publications are designed, researched and written to provide timely and insightful information and data on focused market segments, with the aim of providing market participants with the essential knowledge to refine and execute their marketing plans and financial targets.

Ordering Information

Orders may be placed via postal mail, e-mail or fax. Orders not accompanied by a purchase order must contain a telephone number for verification, and clearly indicate the physical shipping address. Orders which are not prepaid must indicate the billing address. There is no charge for handling and shipping for destination addresses within the continental US.

Payment

We accept the following forms of payment:

Company Check: Please make checks payable to 'Greystone Associates'

Credit Cards: We accept MasterCard, Visa and American Express

Wire Transfers: See 'Wire Transfers' below for more information

Orders Outside the U.S.

Orders must be prepaid via credit card, company check in US funds and drawn on a US bank, or wire transfer. There is a \$50 per copy shipping and handling charge for international shipments.

Wire Transfers: TD Banknorth
300 Franklin Street
Manchester, NH 03103
(Call for Account Information)

Mailing Address: Greystone Associates
Client Services
P.O. Box 1362
Amherst, NH 03031

Pediatric Drug Delivery: Evolving Dosage Forms, Emerging Opportunities

Select	Format	Price (U.S. funds)	Total
<input type="checkbox"/>	Electronic	\$3,850.00	
<input type="checkbox"/>	Site License	\$4,850.00	
<input type="checkbox"/>	Enterprise License	\$6,500.00	
Total Payment (U.S. funds)			

Method of Payment: Company Check    Wire Transfer (International)

Card Number: _____ Name on Card _____

Expiration Date: _____ CVV _____ Signature _____

Billing Information	Shipping Information
Name:	<input type="checkbox"/> Click here if same as Billing Information Name:
Title:	Title:
Company:	Company:
Street Address:	Street Address:
City,State/Province:	City,State/Province:
Country/Postal Code:	Country/Postal Code:
Phone:	Phone:
Fax:	Fax:
Email:	Email: